We serve Chemical Name:3-Hydroxy-2-methoxybenzaldehyde CAS:66495-88-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Hydroxy-2-methoxybenzaldehyde
CAS.NO:66495-88-3
Synonyms:Benzaldehyde,3-hydroxy-2-methoxy;3-hydroxy-2-methoxy-benzaldehyde;3-Hydroxy-2-methoxy-benzaldehyd;2-methoxy-3-hydroxybenzaldehyde
Molecular Formula:C8H8O3
Molecular Weight:152.14700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:278.374ºC at 760 mmHg
Density:1.232g/cm3
Index of Refraction:1.588
PSA:46.53000
Exact Mass:152.04700
LogP:1.21330
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzaldehyde,3-hydroxy-2-methoxy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methoxy-3-hydroxybenzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Hydroxy-2-methoxy-benzaldehyd Use and application,2-methoxy-3-hydroxybenzaldehyde technical grade,usp/ep/jp grade.
Related News: Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 3-Hydroxy-2-methoxybenzaldehyde manufacturer The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 3-Hydroxy-2-methoxybenzaldehyde supplier Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 3-Hydroxy-2-methoxybenzaldehyde vendor AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said. 3-Hydroxy-2-methoxybenzaldehyde factory ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib.
